Omalizumab: A recombinant humanized anti-IgE antibody for allergic asthma

American Journal of Health-System Pharmacy

Volumn 61, Issue 14, 2004, Pages 1449-1459

  Ruffin, Charnelda G ^a,b   Busch, Benita E ^b,c  

^a KAISER PERMANENTE   (United States)

^b ACS State Healthcare   (United States)

^c NORTHSIDE HOSPITAL   (United States)

Author keywords

Adolescents; Antibodies; Asthma; Dosage; Mechanism of action; Omalizumab; Pediatrics; Pharmacoeconomics; Pharmacokinetics; Toxicity

Indexed keywords

ANTIHISTAMINIC AGENT; BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; IMMUNOGLOBULIN E ANTIBODY; LEUKOTRIENE; OMALIZUMAB; PLACEBO; RECOMBINANT DNA; SALBUTAMOL; SALMETEROL; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; XANTHINE; IMMUNOGLOBULIN E; MONOCLONAL ANTIBODY;

ALLERGIC ASTHMA; CLINICAL TRIAL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; INJECTION SITE; PARESTHESIA; PEANUT ALLERGY; PERENNIAL RHINITIS; PHARYNGITIS; PRIORITY JOURNAL; REVIEW; SINUSITIS; SKIN ALLERGY; TISSUE REACTION; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VIRUS INFECTION; ADOLESCENT; ADULT; ASTHMA; BIOAVAILABILITY; BLOOD; CHILD; CLASSIFICATION; CONTROLLED CLINICAL TRIAL; ECONOMICS; HOSPITALIZATION; METABOLISM; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ASTHMA; BIOLOGICAL AVAILABILITY; CHILD; HUMANS; IMMUNOGLOBULIN E; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX;

EID: 5144227805     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.14.1449     Document Type: Review

References (46)

1. Centers for Disease Control and Prevention. Asthma prevalence, health care use and mortality, 2000-2001. www.cdc. gov/nchs/products/pubs/pubd/hestats/ asthma/asthma.htm (accessed 2003 Jul 28).
2. Boulet L, Chapman KR, Cote J et al. Inhibitory effects of anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med. 1997; 155:1835-40.
3. Godard P, Chanez P, Siraudin L et al. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J. 2002; 19:61-7.
4. Serra-Batlles I, Morejon E, Comella A et al. Costs of asthma according to the degree of severity. Eur Respir J. 1998; 12:1322-6.
5. Hoskins G, McCowan C, Neville RG et al. Risk factors and cost associated with an asthma attack. Thorax. 2000; 55:19-24.
6. Weiss KB, Sullivan SD. Current reviews of allergy and clinical immunology: the health economics of asthma and rhinitis. Part I. Assessing the economic impact. J Allergy Clin Immunol. 2001; 107:3-8.
7. National Heart, Lung, and Blood Institute. Guidelines for the diagnosis and management of asthma. www.nhlbi. nih.gov/guidelines/asthma/asthgdln.pdf (accessed 2003 Aug 4).
8. Busse WW, Lemanske RF. Advances in immunology: asthma. N Engl J Med. 2001; 344:350-62.
9. Stein RT, Sherrill D, Morgan WJ et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999; 354:541-5.
10. Cookson W. The alliance of genes and environment in asthma and allergy. Nature. 1999;402(suppl):B5-11.
11. Venables K, Chan-Yeung M. Occupational asthma. Lancet. 1997; 349:1465-9.
12. Johansson SG, Haahtela T, O'Byrne PM. Omalizumab and the immune system: an overview of preclinical and clinical data. Ann Allergy Asthma Immunol. 2002; 89:132-8.
13. Milgrom H, Fick RB, Su JQ et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med. 1999; 341:1966-73.
14. Sunyer J, Anto JM, Sabria J et al. Respiratory pathophysiologic responses: relationship between serum IgE and airway responsiveness in adults with asthma. J Allergy Clin Immunol. 1995; 95:699-706.
15. MacGlashan DW, Bochner BS, Adelman DC et al. Down-regulation of FCεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997; 158:1438-45.
16. Burrows B, Martinez FD, Halonen M et al. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med. 1989; 320:271-7.
17. Easthope S, Jarvis B. Omalizumab. Drugs. 2001; 61:253-60.
18. Liu J, Lester P, Builder S et al. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry. 1995; 34:10474-82.
19. Data on file. Genentech, Inc., and Novartis Pharmaceuticals Corp.
20. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, omalizumab, Xolair, rhuMAb-E25. Biodrugs. 2002; I6:380-6.
21. Xolair (omalizumab) package insert. South San Francisco, CA: Genentech, Inc.; East Hanover, NJ: Novartis Pharmaceuticals Corp.; 2003 Jun.
22. Casale T, Bernstein I, Busse W et al. Use of anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol. 1997; 100:110-21.
23. Soler M, Matz J, Townley R et al. The anti-IgE omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001; 18:254-61.
24. Buhl R. Omalizumab improves quality of life in adult patients with allergic asthma: a review. Respir Med. 2003; 97:123-9.
25. Finn A, Gross G, van Bavel J et al. Omalizumab improved asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol. 2003; 111:278-84.
26. Busse W, Corren I, Lanier BQ et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001; 108:184-90.
27. Milgrom H, Berger W, Nayak A et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001; 108:E36-45.
28. Casale TB, Condemi J, LaForce C et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis. JAMA. 2001; 286:2956-67.
29. Clinical Pharmacology. Omalizumab monograph, www.cp.gsm.com (accessed 2003 Aug 21).
30. Conner SJ. Evaluation and treatment of the patient with allergic rhinitis. J Fam Pract. 2002; 51:883-90.
31. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol. 2001; 108(suppl):S2-8.
32. Guerra S, Sherrill D, Martinez F et al. Rhinitis as an independent risk factor for adult-onset asthma. J Allergy Clin Immunol. 2002; 109:419-25.
33. Linneberg A, Nielsen N, Frolund L et al. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy study. Allergy. 2002; 57:1048-52.
34. Settipane R, Hagy G, Settipane G. Long-term risk factors for developing asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Proc. 1994; 15:21-5.
35. Togias A. Rhinitis and asthma: evidence for respiratory system integration. J Allergy Clin Immunol. 2003; 111:1171-83.
36. Chervinsky P, Casale T, Townley R et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2003; 91:160-7.
37. Novak N, Beiber T. The skin as a target for allergic diseases. Allergy. 2000; 55:103-7.
38. Belsito DV. The diagnostic evaluation, treatment, and prevention of allergic contact dermatitis in the new millennium. J Allergy Clin Immunol. 2000; 105:409-20.
39. Leung DY, Bock SA. Progress in peanut allergy research: are we closer to a cure? J Allergy Clin Immunol. 2003; 112:12-4.
40. Sampson HA. Peanut allergy. N Engl J Med. 2002; 346:1294-9.
41. Vidas P, Perelman B. Activated charcoal forms non-IgE binding complexes with peanut proteins. J Allergy Clin Immunol. 2003; 112:175-9.
42. Leung DY, Sampson HA, Yunginger IW et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med. 2003; 348:986-93.
43. Corren J, Casale T, Deniz Y et al. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol. 2003; 111:87-90.
44. American Lung Association. Trends in asthma morbidity and mortality, March 2003. www.lungusa.org/data/asthma/ asthmal.pdf (accessed 2003 Sep 9).
45. Lacey CF, Armstrong LL, Goldman MP et al., eds. Drug information handbook 2002-2003. In: Aberg JA, Alvarez W, Au D et al., Hudson, OH: Lexi-Comp Inc.; 2002:41-43, 149-151, 186-188, 572-573, 587-592.
46. Azmacort (triamcinolone acetonide) package insert. Bridgewater, NJ: Aventis Pharmaceuticals; 2003 May.